OBI Pharma USA, Inc. プレスリリース一覧


OBI-902 has been granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Nov 17, 2025 21:00 JST
OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology.
More info..

新着プレスリリース


もっと見る >>